

Biopharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Finished Dosage Form, Active Pharmaceutical Ingredients (APIs)), By Biologics (Monoclonal Antibodies (mAbs), Vaccines, Others), By Expression System (Mammalian, Non-Mammalian), By Scale of Operation (Commercial, Research (Clinical and Preclinical)), By Company Size (Large and Very Large Companies, Small and Mid-sized Companies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-03-20 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Biopharmaceutical Contract Manufacturing Market Analysis and Insights

The Biopharmaceutical Contract Manufacturing Market size is anticipated to reach USD 17.20 Billion in 2022 and it is projected to reach USD 26.46 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Biopharmaceutical Contract Manufacturing Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Biopharmaceutical Contract Manufacturing Market growth, Size report provides a comprehensive analysis of the Medical Devices industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Biopharmaceutical Contract Manufacturing Market includes major suppliers & Independent Consultants among others.

Global Market Scope and Biopharmaceutical Contract Manufacturing Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Biopharmaceutical Contract Manufacturing Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Biopharmaceutical Contract Manufacturing Market Country Level Analysis

The Global Biopharmaceutical Contract Manufacturing Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Biopharmaceutical Contract Manufacturing Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Biopharmaceutical Contract Manufacturing Market

Some of the other major highlights of the demand for Biopharmaceutical Contract Manufacturing Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Biopharmaceutical Contract Manufacturing Market during the forecast period.

Merck KGAA

AGC Biologics

Catalent

FUJIFILM

Patheon

Piramal Pharma Solutions

Pfizer

Serum Institute of India

WuXi Biologics

Samsung BioLogics

Thermo Fisher Scientific Inc.

AbbVie Inc.

Emergent BioSolutions

Biocon

BioCina

Ajinomoto

Albany Molecular Research Inc.

Asymchem

Cobra Biologics

Charles River Laboratories

Goodwin Biotechnology

KBI Biopharma

Market Segmentation

The Global Biopharmaceutical Contract Manufacturing Market Share, Demand provides the most up-to-date Medical Devices industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

By Product

Finished Dosage Form
Active Pharmaceutical Ingredients (APIs)

By Biologics

Monoclonal Antibodies (mAbs)
Vaccines
Others

By Expression System

Mammalian
Non-Mammalian

By Scale of Operation

Commercial
Research (Clinical and Preclinical)

By Company Size

Large and Very Large Companies
Small and Mid-sized Companies

Regions Coverd

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Russia
Nordic
Benelux
Rest of Europe

APAC

China
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Biopharmaceutical Contract Manufacturing Market Size Analysis
 - 6.1 By Product
 - 6.1.1 Finished Dosage Form
 - 6.1.2 Active Pharmaceutical Ingredients (APIs)
 - 6.2 By Biologics
 - 6.2.1 Monoclonal Antibodies (mAbs)
 - 6.2.2 Vaccines
 - 6.2.3 Others
 - 6.3 By Expression System
 - 6.3.1 Mammalian
 - 6.3.2 Non-Mammalian
 - 6.4 By Scale of Operation
 - 6.4.1 Commercial
 - 6.4.2 Research (Clinical and Preclinical)
 - 6.5 By Company Size
 - 6.5.1 Large and Very Large Companies
 - 6.5.2 Small and Mid-sized Companies
- 7 North America Market Analysis
 - 7.1 By Product
 - 7.1.1 Finished Dosage Form
 - 7.1.2 Active Pharmaceutical Ingredients (APIs)
 - 7.2 By Biologics
 - 7.2.1 Monoclonal Antibodies (mAbs)
 - 7.2.2 Vaccines
 - 7.2.3 Others
 - 7.3 By Expression System
 - 7.3.1 Mammalian

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.2 Non-Mammalian
- 7.4 By Scale of Operation
 - 7.4.1 Commercial
 - 7.4.2 Research (Clinical and Preclinical)
- 7.5 By Company Size
 - 7.5.1 Large and Very Large Companies
 - 7.5.2 Small and Mid-sized Companies
- 7.5 U.S.
- 7.6 Canada
- 8 Europe Market Analysis
 - 8.1 By Product
 - 8.1.1 Finished Dosage Form
 - 8.1.2 Active Pharmaceutical Ingredients (APIs)
 - 8.2 By Biologics
 - 8.2.1 Monoclonal Antibodies (mAbs)
 - 8.2.2 Vaccines
 - 8.2.3 Others
 - 8.3 By Expression System
 - 8.3.1 Mammalian
 - 8.3.2 Non-Mammalian
 - 8.4 By Scale of Operation
 - 8.4.1 Commercial
 - 8.4.2 Research (Clinical and Preclinical)
 - 8.5 By Company Size
 - 8.5.1 Large and Very Large Companies
 - 8.5.2 Small and Mid-sized Companies
 - 8.5 U.K.
 - 8.6 Germany
 - 8.7 France
 - 8.8 Spain
 - 8.9 Italy
 - 8.10 Russia
 - 8.11 Nordic
 - 8.12 Benelux
 - 8.13 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Product
 - 9.1.1 Finished Dosage Form
 - 9.1.2 Active Pharmaceutical Ingredients (APIs)
 - 9.2 By Biologics
 - 9.2.1 Monoclonal Antibodies (mAbs)
 - 9.2.2 Vaccines
 - 9.2.3 Others
 - 9.3 By Expression System
 - 9.3.1 Mammalian
 - 9.3.2 Non-Mammalian
 - 9.4 By Scale of Operation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.1 Commercial
- 9.4.2 Research (Clinical and Preclinical)
- 9.5 By Company Size
 - 9.5.1 Large and Very Large Companies
 - 9.5.2 Small and Mid-sized Companies
- 9.5 China
- 9.6 Korea
- 9.7 Japan
- 9.8 India
- 9.9 Australia
- 9.10 Taiwan
- 9.11 South East Asia
- 9.12 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Product
 - 10.1.1 Finished Dosage Form
 - 10.1.2 Active Pharmaceutical Ingredients (APIs)
 - 10.2 By Biologics
 - 10.2.1 Monoclonal Antibodies (mAbs)
 - 10.2.2 Vaccines
 - 10.2.3 Others
 - 10.3 By Expression System
 - 10.3.1 Mammalian
 - 10.3.2 Non-Mammalian
 - 10.4 By Scale of Operation
 - 10.4.1 Commercial
 - 10.4.2 Research (Clinical and Preclinical)
 - 10.5 By Company Size
 - 10.5.1 Large and Very Large Companies
 - 10.5.2 Small and Mid-sized Companies
 - 10.5 UAE
 - 10.6 Turkey
 - 10.7 Saudi Arabia
 - 10.8 South Africa
 - 10.9 Egypt
 - 10.10 Nigeria
 - 10.11 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Product
 - 11.1.1 Finished Dosage Form
 - 11.1.2 Active Pharmaceutical Ingredients (APIs)
 - 11.2 By Biologics
 - 11.2.1 Monoclonal Antibodies (mAbs)
 - 11.2.2 Vaccines
 - 11.2.3 Others
 - 11.3 By Expression System
 - 11.3.1 Mammalian

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.2 Non-Mammalian
- 11.4 By Scale of Operation
 - 11.4.1 Commercial
 - 11.4.2 Research (Clinical and Preclinical)
- 11.5 By Company Size
 - 11.5.1 Large and Very Large Companies
 - 11.5.2 Small and Mid-sized Companies
- 11.5 Brazil
- 11.6 Mexico
- 11.7 Argentina
- 11.8 Chile
- 11.9 Colombia
- 11.10 Rest of LATAM
- 12 Competitive Landscape
 - 12.1 Global Biopharmaceutical Contract Manufacturing Market Share By Players
 - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis
 - 13.1.6 Recent Developments
 - 13.2 AGC Biologics
 - 13.3 Catalent
 - 13.4 FUJIFILM
 - 13.5 Patheon
 - 13.6 Piramal Pharma Solutions
 - 13.7 Pfizer
 - 13.8 Serum Institute of India
 - 13.9 WuXi Biologics
 - 13.10 Samsung BioLogics
 - 13.11 Thermo Fisher Scientific Inc.
 - 13.12 AbbVie Inc.
 - 13.13 Emergent BioSolutions
 - 13.14 Biocon
 - 13.15 BioCina
 - 13.16 Ajinomoto
 - 13.17 Albany Molecular Research Inc.
 - 13.18 Asymchem
 - 13.19 Cobra Biologics
 - 13.20 Charles River Laboratories
 - 13.21 Goodwin Biotechnology
 - 13.22 KBI Biopharma
- 14 Research Methodology
 - 14.1 Research Data

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
- 14.1.2 Primary Data
 - 14.1.2.1 Key data from primary sources
 - 14.1.2.2 Breakdown of primaries
- 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
- 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
- 14.3 Research Assumptions
 - 14.3.1 Assumptions
- 14.4 Limitations
- 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Biopharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Finished Dosage Form, Active Pharmaceutical Ingredients (APIs)), By Biologics (Monoclonal Antibodies (mAbs), Vaccines, Others), By Expression System (Mammalian, Non-Mammalian), By Scale of Operation (Commercial, Research (Clinical and Preclinical)), By Company Size (Large and Very Large Companies, Small and Mid-sized Companies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-03-20 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Job title*

Company Name*

Address*

Zip Code*

EU Vat / Tax ID / NIP number*

City*

Country*

Date

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com